Edouard Bardou‐Jacquet, Marie de Tayrac, Jean Mosser, Yves Deugnier – 18 April 2015

Adriaan J. van der Meer – 18 April 2015

Jun Zhao, Matthew W. Lawless – 18 April 2015

Adam Doyle, Rania N. Rabie, Arastoo Mokhtari, Mark Cattral, Anand Ghanekar, David Grant, Paul Greig, Gary Levy, Leslie Lilly, Ian McGilvray, Markus Selzner, Nazia Selzner, Eberhard L. Renner – 17 April 2015 – Because of a persistent discrepancy between the demand for liver transplantation (LT) and the supply of deceased donor organs, there is an interest in increasing living donation rates at centers trained in this method of transplantation. We examined a large socioeconomically heterogeneous cohort of patients listed for LT to identify recipient factors associated with living donation.

Peng Soon Koh, See Ching Chan, Kenneth Siu‐Ho Chok, William Wei Sharr, Tiffany Cho-Lam Wong, Sui Ling Sin, Chung Mau Lo – 17 April 2015 – Improved outcomes have been shown in liver transplantation (LT) with portal vein thrombosis (PVT). However, PVT is still discovered incidentally during surgery despite careful preoperative imaging. Data are limited comparing the outcomes of incidental PVT with PVT diagnosed via preoperative imaging before LT. This study aims to compare the overall outcomes of patients with PVT.

Faisal Saud Dar, Abu Bakar Hafeez Bhatti, Abdul‐Wahab Dogar, Haseeb Zia, Sadaf Amin, Atif Rana, Rashid Nazer, Nasir Ayub Khan, Etizaz‐ud‐din Khan, Muhammad Zameer Rajput, Muhammad Salih, Najmul Hassan Shah – 17 April 2015 – Living donor liver transplantation (LDLT) is the only treatment option for patients with end‐stage liver disease (ESLD) where cadaveric donors are not available. In developing countries, the inception of LDLT programs remains a challenge. The first successful liver transplantation program in Pakistan started transplantation in 2012.

Lynn A. Fussner, Julie K. Heimbach, Chun Fan, Ross Dierkhising, Elizabeth Coss, Michael D. Leise, Kymberly D. Watt – 16 April 2015 – The evolution of metabolic and cardiovascular disease (CVD) complications after liver transplantation (LT) is poorly characterized. We aim to illustrate the prevalence of obesity and metabolic syndrome (MS), define the cumulative incidence of CVD, and characterize risk factors associated with these comorbidities after LT. A retrospective review of 455 consecutive LT recipients from 1999 to 2004 with an 8‐ to 12‐year follow‐up was performed.

Thierry Gustot, Javier Fernandez, Elisabet Garcia, Filippo Morando, Paolo Caraceni, Carlo Alessandria, Wim Laleman, Jonel Trebicka, Laure Elkrief, Corinna Hopf, Pablo Solís‐Munoz, Faouzi Saliba, Stefan Zeuzem, Augustin Albillos, Daniel Benten, José Luis Montero‐Alvarez, Maria Teresa Chivas, Mar Concepción, Juan Córdoba, Aiden McCormick, Rudolf Stauber, Wolfgang Vogel, Andrea de Gottardi, Tania M.

Yael R. Nobel, Kimberly A. Forde, Linda Wood, Katarzyna Cartiera, Armando S. Munoz‐Abraham, Peter S. Yoo, Peter L. Abt, David S. Goldberg – 11 April 2015 – Living donor liver transplantation (LDLT) is a comparable alternative to deceased donor liver transplantation and can mitigate the risk of dying while waiting for transplant. Although evidence exists of decreased utilization of living donor kidney transplants among racial minorities, little is known about access to LDLT among racial/ethnic minorities.

Katharina Esser‐Nobis, Christian Harak, Philipp Schult, Yuri Kusov, Volker Lohmann – 11 April 2015 – Hepatitis A virus (HAV) and hepatitis C virus (HCV) are two positive‐strand RNA viruses sharing a similar biology, but causing opposing infection outcomes, with HAV always being cleared and HCV establishing persistence in the majority of infections. To gain deeper insight into determinants of replication, persistence, and treatment, we established a homogenous cell‐culture model allowing a thorough comparison of RNA replication of both viruses.